Catheter Precision, Inc. (VTAK) Financial Ratios
9 years of historical data (2016–2024) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.23
↓-100% vs avg
5yr avg: 74.03
30Y Low2.4·High125.0
ROE
↑
-101.0%
↓+53% vs avg
5yr avg: -215.1%
30Y Low-463%·High-101%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VTAK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Catheter Precision, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $28M | $422M | $1.2B | $1.5B | $2.4B | $2.8B | $7.4B | — | — |
| Enterprise Value | $282262 | $27M | $419M | $1.1B | $1.5B | $2.4B | $2.8B | $7.3B | — | — |
| P/E Ratio → | -0.12 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.26 | 66.59 | 954.30 | 82653.53 | 68037.27 | 9260.53 | 392.03 | 1180.12 | — | — |
| P/B Ratio | 0.23 | 2.38 | 19.90 | 124.96 | 109.47 | 113.42 | 85.14 | 110.70 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VTAK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 64.01 | 947.08 | 81520.74 | 67456.32 | 9187.09 | 390.49 | 1169.97 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
VTAK Profitability
Margins and return-on-capital ratios measuring operating efficiency
Catheter Precision, Inc. earns an operating margin of -2676.9%. Operating margins have expanded from -192578.6% to -2676.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -101.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.0% | 90.0% | 93.2% | -1050.0% | -6990.9% | -738.6% | -22.9% | 32.8% | 29.0% | 47.5% |
| Operating Margin | -2676.9% | -2676.9% | -17674.0% | -192578.6% | -133027.3% | -13668.3% | -801.9% | -498.0% | -302.6% | -70.2% |
| Net Profit Margin | -3962.6% | -3962.6% | -15966.5% | -191892.9% | -113954.5% | -13917.0% | -791.2% | -492.8% | -302.6% | -70.3% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -101.0% | -101.0% | -463.5% | -234.3% | -144.0% | -132.8% | -114.1% | -104.4% | — | — |
| ROA | -56.9% | -56.9% | -296.7% | -141.8% | -92.0% | -93.0% | -96.4% | -72.3% | -207.6% | -71.9% |
| ROIC | -58.8% | -58.8% | -1027.8% | — | -1454.6% | -219.5% | -342.2% | -721.3% | — | — |
| ROCE | -41.7% | -41.7% | -416.4% | -216.4% | -141.6% | -112.5% | -109.6% | -81.2% | -301.8% | -134.0% |
VTAK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $3M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.02 | — | 0.17 | 0.23 | 0.11 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.15 | -1.71 | -0.93 | -0.90 | -0.33 | -0.95 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -123.55 | -123.55 | — | — | -2926.60 | -327.79 | -230.92 | -2225.71 | -4440.00 | -1399.33 |
Net cash position: cash ($3M) exceeds total debt ($2M)
VTAK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.58x means Catheter Precision, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.22x to 1.58x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.58 | 1.58 | 1.68 | 2.22 | 3.17 | 3.56 | 5.28 | 11.64 | 3.81 | 1.96 |
| Quick Ratio | 1.56 | 1.56 | 1.67 | 2.22 | 2.99 | 3.45 | 4.88 | 11.28 | 3.36 | 1.64 |
| Cash Ratio | 1.38 | 1.38 | 1.44 | 2.09 | 2.79 | 3.08 | 4.49 | 10.81 | 3.13 | 1.45 |
| Asset Turnover | — | 0.02 | 0.01 | 0.00 | 0.00 | 0.01 | 0.16 | 0.08 | 0.52 | 1.02 |
| Inventory Turnover | 1.27 | 1.27 | 0.68 | — | 1.58 | 2.48 | 3.19 | 2.01 | 3.48 | 3.61 |
| Days Sales Outstanding | — | 60.83 | 113.13 | — | 348.41 | 33.82 | 39.85 | 77.00 | 32.15 | 24.00 |
VTAK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Catheter Precision, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $3M | $5M | $1M | $101000 | $33980 | $10516 | $7384 | $9683 | $9683 |
Peer Comparison
Compare VTAK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VTAKYou | $1M | -0.1 | — | — | 90.0% | -2676.9% | -101.0% | -58.8% | — |
 ATRC | $1B | -109.5 | 73.2 | 27.6 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 BEAT | $36M | -1.4 | — | — | — | — | -987.3% | — | — |
 IRTC | $4B | -86.8 | — | 114.8 | 70.6% | -4.9% | -36.6% | -5.2% | — |
 ELMD | $223M | 31.3 | 19.2 | 20.1 | 78.1% | 15.1% | 17.2% | 25.6% | 0.0 |
 BSX | $80B | 27.8 | 24.2 | 21.9 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 ABT | $147B | 11.0 | 15.4 | 23.1 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 MDT | $98B | 21.1 | 14.1 | 18.8 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 JNJ | $533B | 38.2 | 18.5 | 26.9 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 SYK | $109B | 34.0 | 19.8 | 25.5 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 PCOR | $8B | -79.5 | — | 37.4 | 78.4% | -8.9% | -7.9% | -9.7% | — |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See VTAK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VTAK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VTAK vs ATRC
Side-by-side business, growth, and profitability comparison vs AtriCure, Inc..
Start ComparisonVTAK — Frequently Asked Questions
Quick answers to the most common questions about buying VTAK stock.
What is Catheter Precision, Inc.'s P/E ratio?
Catheter Precision, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Catheter Precision, Inc.'s ROE?
Catheter Precision, Inc.'s return on equity (ROE) is -101.0%. The historical average is -184.9%.
Is VTAK stock overvalued?
Based on historical data, Catheter Precision, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Catheter Precision, Inc.'s profit margins?
Catheter Precision, Inc. has 90.0% gross margin and -2676.9% operating margin.